The French biotech said the cash injection – which follows a €45 million Series A in 2020 – will also help it bring forward the first development candidate in a collaboration signed with gene-editing specialist Intellia Therapeutics last year, currently in the early-discovery stage.
It has turned to its existing investors to fund the latest round, which was led by Jeito Capital and UPMC Enterprises, with backing from 4BIO Capital, Ysios Capital, Bpifrance, and Foundation Fighting Blindness’s RD Fund.
